Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 3:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Major Depressive Disorder Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Heart Rate Variability in Depression

NCT02525978
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Video Task, Imaginal Task
Behavioral · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Jun 7, 2026, 3:14 AM EDT
Completed Not applicable Interventional

Effects of Respiratory-Gated Transcutaneous Vagal Nerve Stimulation in Major Depression (Phase 1)

NCT04607226
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Active transcutaneous vagus nerve stimulation, Sham transcutaneous vagus nerve stimulation
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
24 Years to 45 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Jun 7, 2026, 3:14 AM EDT
Completed No phase listed Observational

Real-life Effectiveness of Vortioxetine in Depression

NCT03555136
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Vortioxetine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years and older
Enrollment
992 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
31
States / cities
Dothan, Alabama • Tucson, Arizona • Newport Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Jun 7, 2026, 3:14 AM EDT
Terminated Phase 4 Interventional Results available

Promoting Enhanced Pharmacotherapy Choice Through Immunomarkers Evaluation in Depression

NCT03993457
View directory record Official record
Conditions
Depression
Interventions
Escitalopram, Bupropion
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Jun 7, 2026, 3:14 AM EDT
Completed Phase 3 Interventional Results available

Major Depressive Disorder With Mixed Features - Extension

NCT01423253
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Lurasidone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
17
States / cities
Birmingham, Alabama • Escondido, California • Garden Grove, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Jun 7, 2026, 3:14 AM EDT
Suspended Phase 4 Interventional

IM Ketamine vs Midazolam for Suicidal ER Patients

NCT04640636
View directory record Official record
Conditions
Depression, Unipolar, Depression, Bipolar, Suicidal Ideation
Interventions
Ketamine hydrochloride injection, Midazolam injection
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jun 7, 2026, 3:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

ESTIA: Computerized Intervention Targeting Cognitive Control Deficits in Depressed Adults

NCT02891564
View directory record Official record
Conditions
Major Depression
Interventions
Band Together, Control Mobile 3D video game
Behavioral · Other
Lead sponsor
University of Washington
Other
Eligibility
45 Years to 75 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
2
States / cities
White Plains, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Jun 7, 2026, 3:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2216684 in Healthy Participants

NCT01380691
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2216684, Placebo-matching LY2216684, Placebo-matching alcoholic beverage, Alcoholic beverage
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Jun 7, 2026, 3:14 AM EDT
Recruiting Not applicable Interventional

Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics

NCT04130958
View directory record Official record
Conditions
Major Depressive Episode, Borderline Personality Disorder, Suicide
Interventions
Intermittent Theta Burst Transcranial Magnetic Stimulation (Active), Intermittent Theta Burst Transcranial Magnetic Stimulation (Sham)
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Jun 7, 2026, 3:14 AM EDT
Active, not recruiting Not applicable Interventional

Theta Burst Stimulation for Refractory Depression in Autism Spectrum Disorder

NCT06670040
View directory record Official record
Conditions
ASD, Autism Spectrum Disorder, Autism, Depression - Major Depressive Disorder, MDD
Interventions
Transcranial Magnetic Stimulation, Transcranial Magnetic Stimulation Sham
Procedure
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
13 Years to 26 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jun 7, 2026, 3:14 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive Disorder

NCT01838876
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Antidepressant Therapy (ADT)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
88
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 74 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Jun 7, 2026, 3:14 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder

NCT04479852
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SP-624, Placebo
Drug
Lead sponsor
Sirtsei Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
39
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Jun 7, 2026, 3:14 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Development of Attentional Biases for Affective Cues in Infants of Mothers With Depression

NCT06835855
View directory record Official record
Conditions
Depression - Major Depressive Disorder
Interventions
Passive Viewing Task, Interaction Task
Other
Lead sponsor
Binghamton University
Other
Eligibility
6 Months and older
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Binghamton, New York
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Jun 7, 2026, 3:14 AM EDT
Terminated Phase 1 Interventional

Adaptive tDCS for Treatment-Resistant MDD

NCT02942368
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
tDCS
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jun 7, 2026, 3:14 AM EDT
Completed Phase 2Phase 3 Interventional

Investigating tDCS as a Treatment for Unipolar and Bipolar Depression

NCT01562184
View directory record Official record
Conditions
Unipolar Depression, Bipolar Depression
Interventions
Sham tDCS device, Soterix tDCS device
Device
Lead sponsor
The University of New South Wales
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
Atlanta, Georgia • Towson, Maryland • Cherry Hill, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2015 · Synced Jun 7, 2026, 3:14 AM EDT
Completed Phase 4 Interventional Results available

Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression

NCT00531947
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Selegiline Transdermal System, Placebo
Drug
Lead sponsor
Somerset Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
20
States / cities
Dothan, Alabama • National City, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2014 · Synced Jun 7, 2026, 3:14 AM EDT
Completed Not applicable Interventional Results available

Testosterone Antidepressant Augmentation in Women

NCT01783574
View directory record Official record
Conditions
Depression
Interventions
Testosterone, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Jun 7, 2026, 3:14 AM EDT
Withdrawn Not applicable Interventional

Efficacy of Electronic Cognitive Behavioral Therapy Application to Treat Major Depressive Disorder

NCT01752608
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
eCBT Mood
Behavioral
Lead sponsor
MindApps
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Leesburg, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2015 · Synced Jun 7, 2026, 3:14 AM EDT
Completed Phase 1 Interventional

A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder

NCT03374475
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
JNJ-42847922 20mg, JNJ-42847922 40mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
San Diego, California • San Marcos, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Jun 7, 2026, 3:14 AM EDT
Completed Phase 3 Interventional Results available

The Effects of Wellbutrin (Bupropion) on Residual and Cognitive Symptoms in SSRI-treated Depression

NCT00125957
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Unipolar Depression
Interventions
Wellbutrin, Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2014 · Synced Jun 7, 2026, 3:14 AM EDT
Recruiting No phase listed Observational

The OBSERVE Protocol

NCT06725277
View directory record Official record
Conditions
Major Depression Disorder
Interventions
Spravato, IV Ketamine
Drug
Lead sponsor
Yale University
Other
Eligibility
Not listed
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
6
States / cities
Milford, Connecticut • New Haven, Connecticut • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Jun 7, 2026, 3:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sleep/Wake Cycle and Depression: An Imaging and Treatment Study

NCT04350567
View directory record Official record
Conditions
Depression; Major Depressive Disorder
Interventions
Sleep Deprivation
Other
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 100 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Jun 7, 2026, 3:14 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)

NCT07621237
View directory record Official record
Conditions
Major Depressive Episode (MDE), Major Depressive Disorder (MDD), Depression
Interventions
TNX-102 SL, Placebo sublingual tablet
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
25
States / cities
Phoenix, Arizona • Chino, California • Lemon Grove, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jun 7, 2026, 3:14 AM EDT
Completed Not applicable Interventional Results available

Naltrexone for Antipsychotic-Induced Weight Gain

NCT01866098
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Bipolar Disorder, Severe Major Depression With Psychotic Features
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Jun 7, 2026, 3:14 AM EDT